EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited‐Stage Small Cell Lung Cancer

Fan Ge iD, Guo Lin, Zhenyu Huo, Zhanyu Wang, Nan Sun, Jie He iD

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70125 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Fan Ge und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Neoadjuvant Therapy, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, The National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to explore clinical outcomes and safety of neoadjuvant immunotherapy combined with chemotherapy in limited‐stage small cell lung cancer (SCLC), providing insights for upcoming clinical trials.

Methods

PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched for relevant original articles and conference proceedings, updated through 10 February 2025. Pathological complete response (pCR) rate and major pathological response (MPR) rate were calculated as the major assessments for the clinical outcomes. The incidences of the rate of R0 resection and treatment‐related severe adverse events (tr‐SAE) were considered as the primary outcomes for assessing the safety. Subgroup analyses were conducted according to neoadjuvant therapy cycle and study type.

Results

A total of 114 patients from 6 studies were included. The meta‐analysis results suggested that the pooled rates of pCR and MPR were 35% [95% confidence interval (CI) 14–56] and 49% (95% CI 18–80) in LS‐SCLC patients. In terms of safety, most patients achieved R0 surgical resection [95% (95% CI 85–100)] and the pooled incidence of tr‐SAE was 44% (95% CI 13–76). Meanwhile, all studies reported that there were no deaths during the perioperative period. Subgroup analysis suggests that more than two neoadjuvant therapy cycles may be associated with better clinical outcomes.

Conclusions

In conclusion, the current research findings demonstrate that neoadjuvant immunotherapy has shown promising clinical efficacy and acceptable safety in SCLC. These results provide valuable reference for upcoming clinical trials regarding the optimal neoadjuvant strategy and potential beneficiary populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaNeoadjuvant TherapyLung NeoplasmsImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansTreatment OutcomeNeoplasm Staging

Stichwörter der Autor:innen

SCLCimmunotherapymeta‐analysisneoadjuvant

Autor:innen und Institutionen

  • Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union…

ORCID-Profile: Fan Ge, Jie He

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • The National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Ge, F., Lin, G., Huo, Z., Wang, Z., Sun, N., & He, J. (2025). A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited‐Stage Small Cell Lung Cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70125

Vancouver

Ge F, Lin G, Huo Z, Wang Z, Sun N, He J. A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited‐Stage Small Cell Lung Cancer. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70125

BibTeX
@article{Ge2025,
  author = {Ge, Fan and Lin, Guo and Huo, Zhenyu and Wang, Zhanyu and Sun, Nan and He, Jie},
  title = {A Comprehensive Study on Clinical Outcomes and Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Limited‐Stage Small Cell Lung Cancer},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70125}
}
Kostenlos starten →